首页> 外文期刊>Medicine. >Pulmonary Capillary Hemangiomatosis Associated with Primary Pulmonary Hypertension: Report of 2 New Cases and Review of 35 Cases from the Literature.
【24h】

Pulmonary Capillary Hemangiomatosis Associated with Primary Pulmonary Hypertension: Report of 2 New Cases and Review of 35 Cases from the Literature.

机译:肺毛细血管性血管瘤合并原发性肺动脉高压:2例新病例报告,并文献复习35例。

获取原文
获取原文并翻译 | 示例
           

摘要

Pulmonary capillary hemangiomatosis (PCH) is a rare cause of primary pulmonary hypertension characterized by thin-walled microvessels infiltrating the peribronchial and perivascular interstitium, the lung parenchyma, and the pleura. These proliferating microvessels are prone to bleeding, resulting in accumulation of hemosiderin-laden macrophages in alveolar spaces. Here we report 2 cases of PCH with pulmonary hypertension, 1 of them associated with mechanical intravascular hemolysis, a feature previously reported in other hemangiomatous diseases, but not in PCH. Case 2 was diagnosed by pulmonary biopsy; to our knowledge the patient is the second adult to be treated with interferon alpha-2a. Review of the literature identified 35 patients with PCH and pulmonary hypertension. The prognosis is poor and median survival was 3 years from the first clinical manifestation. Dyspnea and right heart failure are the most common findings of the disease. Hemoptysis, pleural effusion, acropachy, and signs of pulmonary capillary hypertension are less common. Chest X-ray or computed tomography scan usually shows evidence of interstitial infiltrates, pulmonary nodules, or pleural effusion. Hemodynamic features include normal wedge pressures. Radiologic and hemodynamic findings are undifferentiated from those of pulmonary veno-occlusive disease but differ from other causes of primary pulmonary hypertension. Epoprostenol therapy, considered the treatment of choice in patients with primary pulmonary hypertension, may produce pulmonary edema and is contraindicated in patients with PCH. Regression of lesions was reported in 1 patient treated with interferon therapy and 2 other patients stabilized, including our second patient. PCH was treated successfully by lung transplantation in 5 cases. Early recognition of PCH in patients with suspected primary pulmonary hypertension is possible based on clinical and radiologic characteristics. Diagnosis by pulmonary biopsy is essential for allowing appropriate treatment.
机译:肺毛细血管血管瘤病(PCH)是原发性肺动脉高压的罕见原因,其特征是薄壁微血管浸润支气管周围和血管周间质,肺实质和胸膜。这些增生的微血管易于出血,导致携带有含铁血黄素的巨噬细胞积聚在肺泡腔中。在这里,我们报告2例PCH伴有肺动脉高压,其中1例与机械性血管内溶血有关,这是以前在其他血管瘤疾病中报道的特征,但在PCH中没有。病例2经肺活检确诊;据我们所知,患者是第二位接受干扰素α-2a治疗的成年人。文献综述确定了35例PCH和肺动脉高压患者。预后较差,中位生存期为首次临床表现后的3年。呼吸困难和右心衰竭是该病最常见的发现。咯血,胸腔积液,杂技症和肺毛细血管高血压的症状较不常见。胸部X光或计算机断层扫描通常显示间质浸润,肺结节或胸腔积液的证据。血液动力学特征包括正常的楔形压力。放射学和血液动力学发现与肺静脉闭塞性疾病无差异,但与其他原发性肺动脉高压的原因不同。 Epoprostenol治疗被认为是原发性肺动脉高压患者的首选治疗方法,可能会产生肺水肿,并且在PCH患者中禁用。据报道,1例接受干扰素治疗的患者病灶消退,2例其他患者稳定下来,包括我们的第二例患者。肺移植成功治疗PCH 5例。根据临床和影像学特征,可以在疑似原发性肺动脉高压患者中早期识别PCH。肺活检诊断对于进行适当治疗至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号